Repligen Corp

NASDAQ:RGEN

Earnings Call Transcript 2019-Q2

[Operator]

Good day, ladies and gentlemen, and welcome to Repligen Corporation Second Quarter 2019 Earnings Conference Call. My name is Haley, and I will be the operator for your call this morning. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to your host for today's call, Sondra Newman, Global Head of Investor Relations. Please go ahead.

[Sondra Newman, executive]

Great. Haley, thank you. Good morning, and thanks to everyone for joining our call. Today, we're covering financial results for Repligen's second fiscal quarter of 2019. We'll review recent business events and update our financial guidance for the full year. Repligen President and CEO, Tony Hunt, will cover our business highlights; and our CFO, Jon Snodgres, will provide a financial report.

As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning risk factors is included in our annual report on Form 10-K, the current report on Form 8-K, which we are filing today, and other filings that we make with the SEC. Today's comments reflect management's current views, which could change as a result of new information, future events or otherwise. The company does not oblige or commit itself to update forward-looking statements, except as required by law.

During this call, we are providing non-GAAP results and guidance. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this morning, which is posted to Repligen's website and on sec.gov. Non-GAAP figures in today's report include the following: revenue growth at constant currency, gross profit and gross margin, operating expenses, including R&D and SG&A, operating income and operating margin, income tax expense, net income and earnings per share as well as EBITDA and adjusted EBITDA. These adjusted financial measures should not be viewed as alternative to GAAP measures, but are intended to better enable investors to benchmark Repligen's current results against historical performance and the performance of peers when evaluating investment opportunities.

Now I'll turn the call over to Tony Hunt.

[Anthony Hunt, executive]

Thank you, Sondra, and good morning, everyone. Q2 was an excellent and important quarter for the company, as our team continues to execute on our financial and strategic goals. Financially, our overall performance was well ahead of our expectations, delivering 46% organic growth in the second quarter and 42% organic growth in the first half of 2019. Strength in the quarter was across all of our franchises with filtration, chromatography and proteins businesses, each recording organic revenue growth above 40%.

Throughout the first half of this year, order load has remained strong, and we are confident that the momentum in the first half, specifically in filtration and chromatography will carry over into the second half of this year. We clearly have tougher comps in H2, including a flat proteins business, but we still expect overall organic growth for 2019 to be in the range of 29% to 31%. Strategically, we signed a very important deal in April to acquire C Technologies, which we closed in late May. This adds a fourth franchise for Repligen and moves us into process analytics with a focus on at-line and in-line protein concentration measurement.

C Technologies' innovative protein concentration measurement systems also complement our systems, where we can now look to incorporating this technology into our filtration products. Integration activities are well underway, and we have made good progress on our 3 target areas. Number one is commercial, where our goal is to build out the sales team, so we have the right coverage in each of our main regions of North America, Europe and Asia-Pac and realize the full potential of this technology. To date, we have hired 3 of the 7 sales specialists with the goal of completing the hiring by the end of the year. Number two is finance, where our goal will be to align C Technologies to Repligen and public company standards. We are actively building up the finance team in Bridgewater, New Jersey, which we expect to have in place by the end of this quarter. And finally, R&D, where we are increasing our investments in the development of next-gen FlowVPE technology, a disruptive technology in our industry for in-line measurement of protein concentration. Again, there's good alignment here between our teams with a clear investment plan in place for the next 18 months.

Turning now to C Technologies' business performance. For our 1 month of ownership in June, sales came in at $2.2 million, and the business is on track to meet our $16 million to $17 million goal for the 7 months of ownership in 2019. Finally, during the second quarter and into July, we successfully executed on 2 follow-on financings, raising approximately $600 million and adding approximately $290 million in cash to our balance sheet after paying for C Technologies and exchanging our 2016 notes. This puts us in a very strong financial position from which to execute on internal investments and external opportunities as they arise.

So moving now to our Q2 results. As reported today, we had a record quarter with $70.7 million in sales and adjusted operating margins north of 28%. The story of the quarter was, again, the across-the-board strength in all 3 franchises and the increased traction for our products at gene therapy accounts. In filtration, our ATF product line had another record quarter. We continue to see companies scaling up ATF for late-stage and commercial processes. We are very happy with the funnel development with ATF trials up 25% in Q2 versus Q1. Single-use demand continues to be strong, and we have a number of customers moving into commercial manufacturing later this year and into 2020.

Our hollow fiber business also had a very strong quarter. Year-over-year growth was led by our TFF systems and our single-use flow path assemblies, where 25% of the revenue came from gene therapy accounts. Revenue synergies for Spectrum came in over $3 million for the quarter and over $6 million through the first half of 2019. Overall, revenue synergies are now tracking north of $11 million, which has us well ahead of our 3-year goal to deliver between $15 million and $20 million in revenue synergies from this deal.

Finally, our SIUS flat sheet TFF cassette business continues to perform well with another strong quarter and first half of this year. We continue to see platforming of the technology of key accounts. With our next-gen SIUS product line set to launch in late Q4, we are well positioned with this technology for 2020.

Moving to chromatography. Our OPUS prepacked column business delivered another outstanding quarter with revenues well north of 50% year-on-year. The story in the quarter was the across-the-board demand for all column sizes and the continued uptick in demand from gene therapy customers. Through the first half of 2019, gene therapy accounts accounted for 18% of OPUS revenues, up from approximately 10% in prior years. New accounts contributed 23% of revenues in the quarter, and order load was again strong.

As discussed on our last call, we are investing in additional capacity and have decided to accelerate and expand this activity to ensure we are keeping ahead of demand. We expect now to have 4 suites online by the end of 2019 and an additional 9 suites by the end of next year, which will give us capacity to produce 4 to 5x more columns per year than we had in place at the end of 2018.

Our OEM proteins business also had an exceptional quarter, up over 40% organically. Demand for our Protein A ligands was especially strong, which was the main contributor to the overperformance in proteins in the quarter. As discussed on previous calls, we expect growth factor and ligand demand to be very strong in the first half of 2019 and decrease in the second half. This view has not changed. We expect that the H2 proteins business will be flat year-on-year as our 2 main accounts have secured a significant amount of their annual demand in the first half of 2019. 2019 will be the first year since 2015, where we will see growth in proteins, with growth now expected to top 10% for the year.

As we look to the second half of 2019, our focus will be on new product launches, capacity expansion and success of C Technologies' integration. We are very excited about our upcoming TFDF product launch, where we will focus the technology on mAb applications. Our ATF controller and next-gen SIUS products are also set to launch, which will provide good momentum as we kick off 2020.

As our business has accelerated here in 2019, we have invested in people and in capacity. We've added approximately 100 people to the organization year-to-date, excluding C Technologies, and we are on track to complete 3 major CapEx programs in 2019. The first one is the SAP implementation here on the East Coast in Waltham and Marlborough, which will happen in quarter 3. The relocation of our ATF manufacturing from Waltham to Marlborough by the end of the year and the addition of the 4 OPUS suites to support our rapidly expanding chromatography business. These additions and investments will lower our operating margins in the second half of 2019, but we still expect to see strong margin expansion of approximately 200 basis points for the calendar year.

In summary, we had an excellent start to the year. We have delivered on our financial goals, executed on a key M&A, invested in people and infrastructure to scale our company to the next level. And finally, positioned ourselves for the future through a series of equity and debt financings as we continue to execute on our blueprint for growth, which is centered on technology leadership in bioprocessing through internal development and M&A.

I'll now turn the call over to Jon for a financial update.

[Jon Snodgres, executive]

Thank you, Tony, and good morning, everyone. Today, we are reporting our financial results for the second quarter of 2019 as well as updating our financial guidance for the year. Unless otherwise mentioned, all financial measures discussed today reflect non-GAAP measures. Before diving into our quarterly results, I'll take a few minutes to provide some additional color on C Technologies and our recent financing activities, including the impacts on cash, share count and EPS.

First, on May 31, we closed on our acquisition of C Technologies using $195 million of cash and issuing approximately 800,000 new shares of Repligen common stock. We now expect C Technologies' impact on GAAP fully diluted EPS to be a loss of $0.15 to $0.16 versus our prior estimate of a loss of $0.04 to $0.06. This change is associated with the purchase accounting treatment and timing of certain deal-related costs that are cash neutral to the overall deal. On an adjusted basis, we now expect C Technologies to be $0.06 to $0.07 accretive to our 2019 earnings per share compared to the previous range of $0.05 to $0.07. The reconciliation of GAAP to non-GAAP EPS for C Technologies alone includes the following approximate adjustments: Inventory step-up charges of $0.03 per share, acquisition and integration costs of $0.20 per share and intangible amortization of $0.06 per share, partially offset by a $0.07 tax effect of these adjustments.

Next, in the second quarter and here in the start of the third quarter, we completed 2 follow-on offerings to provide the company with financial flexibility. In May, we executed on an equity raise. And in July, we executed on a concurrent equity and convertible debt offering. In conjunction with the convert, we completed a private exchange for 80% of the outstanding notes from our May 2016 convert. We also issued a redemption notice for the remaining 20% of the outstanding notes, which we expect to close in September. The result of the combined effect of our offerings and redemptions is a net $484 million in cash and the issuance of an estimated 7.3 million new shares.

The overall impact to Repligen of these financing activities since our first quarter report is as follows: First, we added approximately $290 million of cash to our balance sheet to use for future business needs and opportunities, net of the cash used to acquire C Technologies and settle our 2016 notes. Second, we improved our coupon rate with our new convert, which is at 0.375% compared to 2.125% on our May 2016 notes, which will lower our quarterly cash interest expense. And third, on our GAAP P&L, we expect to record an estimated $5.7 million in debt extinguishment expense in Q3, and we are estimating noncash interest expenses of $5.1 million in the second half of 2019, both of which will be excluded from our adjusted non-GAAP P&L.

Moving now to our second quarter and first half 2019 financial results. As you've seen in our press release this morning, we delivered very strong financial performance for the second quarter and are again raising both our top and bottom line financial guidance for the year, while we continue to ramp up our investments in capacity, systems and personnel to stay ahead of strong market demand. Specifically, we delivered another record quarter with revenues of $70.7 million with organic growth of 46%, net of a 2.6% headwind from foreign exchange. We also increased adjusted operating income by 190 -- a 159% year-over-year to $20.1 million and realized a 1,200 basis point year-over-year improvement in adjusted operating margin, up to 28.4%. Finally, on the bottom line, we reported 122% year-over-year increase in adjusted EPS to $0.31 per fully diluted share. As Tony mentioned earlier, our 3 product franchises, filtration, chromatography and proteins, continued to perform very well with each of the product franchises growing at least 40% organically compared to the second quarter of 2018.

On a regional basis, for the year-to-date period, direct product revenue growth was strongest in both North America and Asia at approximately 60%, and Europe grew at 20% versus a very tough 2018 comp. Overall, 57% of our direct product revenue for the year-to-date period came from North America, with Europe and Asia accounting for 26% and 17%, respectively. Based on market strength and overall visibility in the third quarter, we continue to expect strong performances from our filtration and chromatography businesses in the second half of 2019. And as Tony mentioned, we expect a slowdown in proteins in H2, given the exceptional growth in the first half of the year. Overall, for the year, we expect that filtration and chromatography will grow at greater than 35% organically, and proteins will grow at greater than 10% organic.

Now moving down our income statement. Adjusted gross profit for the second quarter of 2019 was $41.4 million, representing an increase of 54% or $14.6 million compared to the second quarter of 2018. Adjusted gross margin of 58.6% was a result of strong operational execution, favorable product mix and timing of volume increases that were ahead of our plant capacity investments and systems investments, which will impact us in the second half of 2019.

For the first half of 2019, adjusted gross margin for the company was 57.4%. We expect second half 2019 gross margins to be approximately 200 basis points lower than the first half due to planned increases in expenses related to facility expansion in our Waltham facility, depreciation expenses from investments in plant capacity and our new SAP system and increases in headcount to support higher product volumes flowing through our factories.

With respect to operating expenses. Adjusted research and development costs for the second quarter of 2019 were $5.1 million compared to $5.7 million in the 2018 period. The reduction compared to the second quarter of 2018 was due to timing of a large 2018 investment, a new ligand technology with Navigo GmbH. Overall, adjusted R&D expenses for the second quarter were 7.3% of revenue, and adjusted R&D spend is expected to increase through the second half of the year to support key investments and developments of our new ATF controller technology, TFDF systems as well as investments in C Technologies' pipeline. We expect an overall adjusted R&D expense of approximately 7% of revenue for the full year 2019.

Moving to SG&A, our second quarter of 2019 adjusted SG&A expense was $16.2 million compared to $13.4 million for the second quarter of 2018. The 21% year-over-year increase in adjusted SG&A was tied to the expansion of our commercial organization and infrastructure teams as well as the addition of C Technologies to Repligen. We also expect planned increases in expenses in the second half of 2019 in adjusted SG&A, supporting the expansion of facilities in Waltham, depreciation related to our SAP implementation and other IT investments as well as for the addition of C Technologies to our business. Overall, we expect full year adjusted SG&A expenses to be approximately 26% of overall revenue, and this is reflected in our full year 2019 guidance. For the full year, we expect total operating expenses to come in at 33% to 34% of sales with adjusted operating margin expansion in the range of 200 to 300 basis points.

Moving now to adjusted income and EPS. As I mentioned earlier, our second quarter 2019 adjusted operating income was $20.1 million, a 159 point increase -- percent increase compared to $7.8 million reported in the second quarter of 2018. Our adjusted operating margin was 28.4%, a 1,200 basis point improvement over the second quarter of 2018. Beyond sales volume flow-through and favorable product mix, second quarter operating margin strength benefited from the pacing of the investments in new hires, in operations as well as in IT systems, which are more heavily weighted towards the second half of the year. Adjusted net income for the second quarter of 2019 was $15.3 million, an increase of 147% compared to $6.2 million in the same period in 2018. Adjusted EPS increased to $0.31 per fully diluted share for the second quarter of 2019, up from $0.14 for the second quarter of 2018.

Our cash and cash equivalents, which are GAAP metrics, were $208.9 million at June 30, 2019, reflecting first half of 2019 net cash generation of $15.1 million, inclusive of our May equity offering proceeds of $189.6 million, less $195 million of cash, restricted cash and deal costs paid for the acquisition of C Technologies. In the first half of 2019, we generated free cash flow of $18.4 million, inclusive of $27.5 million of operating cash flow plus $9.1 million of capital investments, primarily related to our ongoing capacity expansion initiatives and SAP implementation program. In addition, our full year 2019 cash balance guidance will reflect an increase of approximately $290 million from the net cash proceeds from financing activities.

Now moving to our 2019 full year guidance. Our GAAP to non-GAAP reconciliations for our 2019 financial guidance are included in the reconciliation tables in today's earnings press release. As previously mentioned, unless otherwise noted, all 2019 financial guidance discussed will be non-GAAP. Please also keep in mind that our 2019 guidance may be impacted by fluctuations in foreign exchange rates beyond our current projection of 1% headwind on sales.

Today, to reflect our acquisition of C Technologies and in recognition of strong market conditions and overall execution, we are increasing our 2019 full year revenue guidance, a GAAP metric, to $264 million to $268 million, an increase of $28 million from the midpoint of our previous range and reflecting growth in the range of 36% to 38% as reported and 29% to 31% on an organic basis. We are holding our adjusted gross margin guidance for 2019 to 56% to 57%, and we are increasing our non-GAAP operating margin guidance to 22.5% to 23.5% of revenue. We are increasing our guidance for adjusted operating income to $60 million to $62 million, an increase of $7.5 million at midpoint from our previous guidance.

In terms of other income and expense, we now expect to see a net full year of income of approximately $2 million, reflecting the reduction in cash interest expense from our new convertible debt instrument as well as interest income from additional cash on hand. We are increasing our 2019 adjusted income tax expense to be approximately 24% of adjusted pretax income. This increase in our annual tax rate is related to effects from the extinguishment of our May 2016 convertible debt as well as changes in the company's methodology for calculating its non-GAAP financial measures to reflect certain tax effects related to acquisition and integration costs, inventory step-up charges, intangible amortization and noncash interest expense. We are also increasing our full year 2019 adjusted net income by $5.5 million at midpoint to a new range of $47 million to $49 million, and the midpoint of our adjusted EPS by $0.09 to a range of $0.94 to $0.98 per fully diluted share. Our adjusted EBITDA range is also being increased by $7.5 million at midpoint to $68 million to $70 million for the full year 2019, with depreciation expenses expected to be approximately $7.5 million and intangible amortization expenses estimated to be approximately $13.5 million, inclusive of C Technologies.

In terms of weighted average fully diluted share count assumptions for 2019, we have increased to 50.1 million weighted average fully diluted shares at year-end, which incorporates the estimated impact of our Q2 and Q3 financing activities as well as our purchase of C Technologies. Weighted average fully diluted shares are expected to be approximately $52 million in Q3 and $53 million in Q4. The company is maintaining its 2019 full year CapEx investment guidance at $18 million to $20 million. We are increasing our 2019 year-end cash and cash equivalents, a GAAP metric, to be in the range of $510 million to $520 million, which includes cash generation from our base business, net proceeds from our recent equity offerings and convert activities, less the cash component of the purchase price of C Technologies and related acquisition fees.

This completes our financial report and guidance update, and I will now turn the call back over to the operator to open the lines for questions.

[Operator]

We will now begin the question-answer session. [Operator Instructions] And the first question comes from the line of Tycho Peterson of JPMorgan.

[Tycho Peterson, analyst]

Tony, I'm wondering if you could talk a little bit more about the protein business, up 40% this quarter. I think you started out talking about it being flat-to-down on the year. You're now talking about it being greater than 10% for the year. So can you talk about what you saw in the quarter on protein? And then, I guess, going forward, should we think about it being back to kind of growth mode, looking a little bit beyond the back half of the year?

[Anthony Hunt, executive]

Yes, sure. So if you think about the proteins business, Q1 and Q2 were actually very different. In Q1, we saw a very strong growth factor business with reasonable single-digit growth in the ligands piece. And then when we got to Q2, it really was all about ligand demand right across the board with both GE and Millipore having very strong demand in the quarter. We were expecting that the first half of the year was going to be stronger based on forecast. It definitely came in a lot stronger than we were forecasting. And when we look at the second half of the year, and we look at the forecast, we can see year-on-year H2 2019 versus H2 2018, that's essentially going to be flat. And obviously, with the strength we saw in the first half, overall growth for the year is definitely going to top 10%.

Now that said, when we move into 2020, as we've spoken about in the past, GE has the option to move up to 50% of their proteins demand -- ligand demand in-house. So we expect as we go through 2020 that some of that volume is definitely going to move across. So I think we'll have a better idea, Tycho, when we get to the end of the year and early February next year exactly what the GE demand is going to look like in 2020. So for now, I think it's a very good year in 2019. I don't think it reflects where proteins is going to be in the future. And I think our real future in proteins is really around the strategy we put in place last year with Navigo and Purolite and developing our own portfolio of affinity ligands, and we expect that those will begin to ramp up. We're seeing some ramp this year, but we'll definitely see an additional ramp next year.

[Tycho Peterson, analyst]

And then it was interesting to see gene therapy. I think you called it out at 25%, and last time, I think it was 15%. So can you just talk a little bit about what you're seeing in that market? How quickly you think you can kind of capture share? And what kind of investments you need to make around the gene therapy business?

[Anthony Hunt, executive]

Yes, the gene therapy market, a year ago, when we talked about it, it was really beginning to take off, but it was still a very small percent of our overall business. The 25% comment in my prepared remarks was around the Spectrum business in Q2. But for sure, when you look at all our products, we're in a good position in gene therapy. And just to be clear, our focus in gene therapy is really around viral vectors and plasmid manufacturing, less so in the CAR-T side of the equation.

But in general, I think we have 3 or 4 products in our portfolio that really address some of the pain points that exist in gene therapy today. So our OPUS pre-packed columns, people really like the convenience of being able to have all the resins pre-packed and ready to go. Our ATF and hollow fiber product lines are doing very well, both upstream and downstream. Our flat sheet cassette business, which is the TangenX business, is well suited to downstream filtration. And when we look at our systems business that we really pulled together in the second half of last year, we're able to sell now systems with our consumables into this customer base. So when you look at overall gene therapy for Repligen, I would expect that probably by the end of the year, we'll be close to 15% of Repligen revenue will be coming from gene therapy accounts.

[Tycho Peterson, analyst]

Okay. And then lastly, are you able to give an order growth rate? I know you gave us one last quarter, I didn't hear that in the prepared comments.

[Anthony Hunt, executive]

Yes, across the board, I mean -- or I don't have an exact growth rate, but orders were very strong across-the-board. Very similar to what we saw probably coming out of Q4 into Q1, probably not as strong as the Q2, but still a very healthy pipeline of orders going into Q3 and Q4. So we're -- I think there's a lot of confidence about our numbers that we've put out for the second half of the year, and a lot of that is coming from a strong order load coming out of the first half into second half.

[Operator]

Your next question is from the line of John Kreger of William Blair.

[John Kreger, analyst]

Tony, just building on your comments about the proteins business in 2020. So given the substantial ramp in growth that you've seen this year over the last, can you just talk about some of the key bottlenecks you've got in the organization to growth, I'm assuming there are some? And are there any other kind of key things you want to call out as we think about '20?

[Anthony Hunt, executive]

Yes. So the -- I think the question is probably broader than proteins, John. So if I look at investments we need to make, we're actually making them. So as we finished off 2018, it was clear to us as we saw the order load there was a few areas that we wanted to invest. And one was definitely on the pre-packed column side. So we've been ramping up with people in the first half of the year. So we've been able to add in a second shift for OPUS, and that's really increased our overall volume of output. But I think as we see visibility from customers around what they want, in 2020, 2021 and 2022, it became clear to us that we really needed to scale OPUS manufacturing by four- to fivefold. And that's why we're adding in 4 suites by the end of this year, an additional 9 next year. So that's a big investment for us, but fully supported by the demand that we're seeing out in the marketplace.

To really free up some of that demand, we made the decision sort of mid-Q1, early Q2 that we would utilize our Marlborough facility, which is really our center of excellence for filtration, and move the ATF products and centralize all filtration products outside what's going on in Rancho and hollow fibers in Marlborough. That will be in place by the end of the year.

And then the rest of our investments have really been around systems, right? So SAP is a big investment for us. We're really happy with the progress we've made. We're at a point now where the East Coast will go live in Q3, and then we'll basically transition then over to bringing the legacy Spectrum sites online in first quarter of next year. So they are the main investments that we're looking at. I think they're going to play out probably not only this year, but also into 2020. But it's what is needed to happen in addition to bringing on additional people so we can stay ahead of the demand curve.

[John Kreger, analyst]

Great. So if you think about your direct business, do you have a view on the sort of sustainable growth that it could support? I'm assuming it's too soon to have a view on sort of demand trends into next year. But what -- could the direct business support, let's say, 20% growth? Or is it too soon to call that?

[Anthony Hunt, executive]

Yes. So it's definitely a little early, but I think given what we've done in -- if you look at 2017, our filtration and chromatography businesses had organic growth of 20% plus. Last year, it was north of 20%. This year, you can see, obviously, through the first half of the year, it's about 35%. So I think a 20% growth for chromatography -- organic growth for chromatography and filtration is absolutely a reasonable assumption. That's something that we aim to do. Obviously, we'll have some headwinds next year with the proteins business. And obviously, to be able to counter that, we have to continue to overdrive on filtration and chromatography. And obviously, the C Tech piece begins to play a role next year as we get a full year of C Technologies in the business.

[John Kreger, analyst]

Great. And one last one. When do you expect to roll out the new TFDF product?

[Anthony Hunt, executive]

Yes, that's going to happen towards the end of this quarter. So as we -- we're in that final stages of the marketing rollout. So by the time we get to November, we'll be able to give everybody an update on the first couple of months of TFDF.

[Operator]

The next question is from the line of Matt Hewitt of Craig-Hallum Capital Group.

[Matthew Hewitt, analyst]

Congratulations on the strong quarter. Just a couple for me, and the first one being a point of clarification. I think last quarter, you talked about adding 6 large-scale manufacturing suites for OPUS in Massachusetts. It sounds like you're going to expand that further. Did you say 4 online by the end of this year and 9 by the end of '20, so a total of 13. Or is it a total of 9, so 4 this year and 5 next year?

[Anthony Hunt, executive]

So you're right. It's 13. It's 4 this year and 9 next year. We will add essentially 10 additional suites into Waltham and 3 into Europe. And one of the decisions we made based on the continued uptick in demand was to centralize our OPUS manufacturing, not in Ravensbrück, but in Breda where we actually own the facility, and we have a lot more space. So that was a small shift that we made, but I think an important one for us for the long-term growth for OPUS and to be able to serve the European customer base.

[Matthew Hewitt, analyst]

Okay. And then as part of that expansion, are you factoring in maybe opportunities to expand that OPUS line? Or is this just for the -- is the expansion just for the existing OPUS line?

[Anthony Hunt, executive]

Well, it covers both. It's definitely the existing product lines. But obviously, we have products in development that will continue to expand the overall OPUS portfolio. So it will manage both.

[Matthew Hewitt, analyst]

Okay. All right. And then maybe last one here. As of last quarter, and you may have just touched on this in the prior response. But at the time of your last call, it sounds like you were evaluating whether to transfer some additional products to the Marlborough facility. Are you still looking at that? Have you made any decisions, anything on that front?

[Anthony Hunt, executive]

Yes. I think when we spoke the last time, we've always said that the Marlborough facility is our center of excellence for filtration. And the Rancho facility, which is the Spectrum facility, that's our center of excellence for hollow fiber modules. So it made sense to us as we looked at the capacity expansion plans that we have in place to move the ATF filtration basically 20 miles down the road to Marlborough and centralize it where we have all the engineering people together, we have the operators together, and we can really leverage the team that we have there.

[Operator]

Your next question is from Brandon Couillard of Jefferies.

[S. Brandon Couillard, analyst]

Tony, if we just look at the outperformance in the second quarter, clearly, based on other peer reports, the markets in bioprocessing are clearly doing quite well. How much would you attribute to just a better market environment versus Repligen-specific drivers?

[Anthony Hunt, executive]

I definitely think it's a bit of both. When you look at the overall market environment, it's really accelerated from where our industry was in the first half of 2017. You could almost say all of 2017 and through the first half of 2018 was pretty tough for everyone. But then we saw last year as we got into the second half that our organic growth began to pick up, and I think that's a reflection too of the strength in the market. So for me, we look at it really from a mAb point-of-view. We think the gene therapy customer base has accelerated, right? There are a lot of companies really working on viral vectors. So that's absolutely helped.

We also have a portfolio of products that are very differentiated in the marketplace. So I think that's the piece that gives us the kind of the above-market growth that we've seen over the last few years. So when you look at what we're doing with OPUS, what we're doing with ATF, what we're doing with our hollow fiber portfolio and systems, it's pretty unique. And I think that's what allows us to be able to grow at above-market growth rate.

And then I think the final part was the commercial integration that we did last year. We paced it, we didn't try and integrate Spectrum and Repligen sales teams all at once. Remember, we went sort of Q1 Asia, Q2 Europe, Q3 North America. So when you think about the last sort of 12 months, we've really just gone through 12 months now of a fully integrated commercial team. And that has really helped us, having everybody selling the whole portfolios complemented and supplemented by specialists.

[S. Brandon Couillard, analyst]

And then given your balance sheet capacity, you sort of speak to your willingness or appetite to perhaps pursue another M&A opportunity kind of what the funnel looks like there and just internally, your ability to perhaps absorb another deal?

[Anthony Hunt, executive]

Yes. So M&A, obviously, it's a big part of what's gotten Repligen to where we are today. Purely with $500 million in the bank, we are in a good position as we look at assets. The M&A situation in 2019 is no different than it was in 2018. We have an active list of companies that we're talking to, but it's no different than 2018. We'll continue to talk if there's a really good opportunity that pops up. I think we're well positioned to be able to execute on it. And obviously, a lot of focus right now is on the C Tech integration, but I think it is probably more straightforward than the Spectrum integration, which was a much bigger integration for us. So we'll see what happens. But I think, expect over the next few years that we'll pace acquisitions very similar to what we've done in the past.

[Operator]

Your next question comes from the line of Paul Knight of Janney Montgomery Scott.

[Paul Knight, analyst]

Tony, on the -- the 2 transaction. I guess, is this -- can you talk about basically how easy you think this will be to integrate into your customer list? And is it -- they have 7 salespeople, you need to sign up all 7, 3 you're done? And could you talk basically about how easily you can tuck it into more and more installations in the industry as you have done with your other acquisitions.

[Anthony Hunt, executive]

Yes, so C Tech is, we're really early innings of doing the integration. So Craig, the C Tech owner and who stayed on and is running the whole business, they've built up a great -- not only a great portfolio of products, but a really great customer base. One of the challenges they have is that the actual selling organization, number of salespeople is relatively small. So one of the things that we have to do to really help them grow beyond what they've been able to do over the last, say, 4 or 5 years is really build up this commercial team. And that's what our #1 focus is. And we're -- our goal is to bring on around 7 salespeople. So think of them as specialists, very like our [ BSS ] model that we have for filtration and chromatography. They'll come online by the end of the year, and that will position us well for 2020 to be able to grow the business with dedicated specialists in North America, dedicated specialists in Asia and dedicated specialists in Europe.

And so the call points, there are some overlap on the call points, especially in the manufacturing setting, but they also have some new call points in the quality control labs, in the formulation labs where we don't call on today. So I expect that when we get into 2020 that our existing bioprocess sales team will be working hand-in-hand with the specialists. Let's call them, C Tech specialists, which really are process analytics specialists to call on the -- hit the call points where -- that are in common, but also be able to accelerate with some of the new call points, which will be in quality control and formulation. So it's a bit of a process, Paul. It's going to take us the best part of this year to really set ourselves up for 2020.

[Operator]

The next question comes from the line of Steve Schwartz of First Analysis.

[Steven Schwartz, analyst]

So the 2 questions I have actually expand on some previous questions, if we could. Just with respect to, Tony, your comments to Tycho's question about gene therapy. In the cell and gene therapy arena, do those orders, do the products you ship, are they significantly different from your traditional markets, if you will, of mAb production, protein production? Are the unit pieces, the components smaller and maybe in higher numbers for an order count, that sort of thing? That's the nature of my question.

[Anthony Hunt, executive]

Yes. So the products are essentially the same. I just think some of the gene therapy accounts are working on a smaller scale than, say, some of the mAb accounts, but it's very similar. And so when we're selling OPUS columns, we might be selling 8-centimeter diameter to 30-centimeter diameter columns. And some of the mAb processes, we might be selling 45, 60s and 80s. So yes, there's a little difference in terms of the size, but it's essentially the same products going into upstream and downstream applications. And I think that's one of the real benefits that we have is that we have a portfolio of products that are very applicable into the gene therapy space, and our sales guys are very aware of where some of those opportunities are. And I think, we've been able to execute on that. And I think very similar to our peers in the space, I think everybody is very, very busy working with the gene therapy customer base.

[Steven Schwartz, analyst]

Okay. Fantastic. Yes, and 15% is 15% of revenue. So -- but glad to hear about that make up, what makes that up.

Second question, just building on Brandon's question with respect to M&A activity and your capacity there. When you talk about the integration and the transformation of C Tech to public company standards, is that being done by the people who carry other roles in the organization? So is it an add-on activity for your staff? Or are you hiring people specifically to handle that activity? And what is your capacity in that regard, that side of maybe executing on the $290 million net that you have?

[Jon Snodgres, executive]

Yes, Steve. So I'll start with that one in terms of the capacity to handle the changeovers to public company standards. We're leveraging some of the resources that we have internally to help position the team and guide them to where we need to be to get up to Repligen standards. But we're also hiring people locally to help administer that and put those programs in place so it's really a combination of the 2, guidance from the current team that we have and leveraging that. And then actually, the heavy lifting and implementation work is mostly going to come from that local team, and we're really happy that we've made one excellent hire so far, and we continue to look for others. And then I'll pass it back over to Tony on -- in terms of M&A.

[Anthony Hunt, executive]

Yes. Maybe, Steve, do you want to repeat the question on M&A? I'm not sure...

[Steven Schwartz, analyst]

Yes, just so -- so with that being said about who is executing these activities. What's your capacity then, now that you have -- you've taken on some additional cash, and you have some more powder in the keg, if you will?

[Anthony Hunt, executive]

I think it's similar to what I said earlier, I don't think 2019 is any different than 2018. We're actively talking to targets, and we'll continue to do that. We were doing that last year as well. And it just -- it's all around timing. It's all around finding the right fit and then reaching a sort of an agreement on what works for both companies. So it's no different. I really think that our pacing on M&A is going to continue to be similar to what you've seen over the last 4 or 5 years. Every 12 to 18 months, I expect that we'll be executing on a deal.

[Steven Schwartz, analyst]

Yes, if you could flavor your M&A pipeline for us at this point, is there any particular bias that you sense with respect to filtration, chromatography or the now newly developing area for you of process analytics?

[Anthony Hunt, executive]

Yes, I'm sure you'll smile, as you hear my answer. But in general, we see opportunities in filtration, we definitely see opportunities in chrom, and obviously, we're just starting in the world of process analytics. And so when we talk to customers, it's -- our 2 companies, they span all 3, right? And so we're not trying to target one versus the other. It's really trying to address some of the gaps that we see that -- and opportunities that we think are out there.

[Operator]

The next question comes from the line of Raghuram Selvaraju of H.C. Wainwright.

[Edward Marks, analyst]

This is Edward on for Ram. Just clarifying on that last point about process analytics. Considering that C Technologies are still being fully integrated into the process. I'm wondering if you're considering -- it sounds like you're still considering M&A into the process analytics space. And might that change as you fully integrate C Technologies and see where they fit in with the synergies around the entire business?

[Anthony Hunt, executive]

Yes. And look, like all our product lines and all our businesses, we jumped into the process analytics space. C Tech made a ton of sense for us. We believe in process analytics. We definitely would like to continue to expand that portfolio led by Craig, and it's just really one of those timing things, and we'll see what happens over the next couple of years.

[Edward Marks, analyst]

Okay. And just a point that you've previously mentioned about having a $2.1 billion total addressable market represented by these segments that you're currently in. I'm wondering if that's considering what you currently have on hand. Or whether there are -- whether you're looking to expand into other areas that would fully bring you up to that $2.1 billion total? Or if that $2.1 billion addressable market is based on things that you would be pursuing in the future?

[Anthony Hunt, executive]

No, it's definitely based on where we are today, and it's our addressable market today based on the products we have in our portfolio and where we're going with those products.

[Edward Marks, analyst]

Okay. So the future addressable market would just increase based on some of the things that you're seeing for any M&A activity or how the market might shift in the future?

[Anthony Hunt, executive]

Yes. Correct.

[Edward Marks, analyst]

Okay. Do you have any guidance towards how big that market might be? Or is it entirely dependent on how things might change?

[Anthony Hunt, executive]

I think it's really entirely dependent on how things might change. But the bioprocessing market is way bigger than $2.1 billion, probably around $8 billion to $9 billion. So you can imagine there's a lot of runway to jump into some other areas in the world of bioprocessing that would expand our overall TAM.

[Operator]

And this concludes our question and session. I would now like to turn the conference back over to Tony Hunt for any closing remarks.

[Anthony Hunt, executive]

I'd just like to thank everybody for joining us today. Obviously, a very strong start to 2019. I think we're really well positioned also for the second half of the year, and we're looking forward to getting back on the call with everybody in November and bringing up to speed on where we are as we finish off 2019. So thanks, everybody for joining.

[Operator]

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.